Next Generation Universal Vaccine Platform: Stronger Preparedness Against Epidemics
As Medical Point Clinical Research Center, we closely follow the latest developments in the medical field and draw attention to potentially groundbreaking research.
Recently announced by the United States Department of Health and Human Services (HHS) and the National Institutes of Health (NIH), the next generation universal vaccine platform called “Generation Gold Standard” is claimed to have strong potential against viruses with epidemic potential.
What is Generation Gold Standard?
The Generation Gold Standard platform is fully publicly owned and developed by the NIH. This initiative uses a beta-propiolactone (BPL) inactivated, whole virus platform. HHS and NIH describe this platform as a “paradigm shift” that brings traditional vaccine technology into the 21st century.
Key Objectives and Features
* Broad Spectrum Protection: The BPL Platform aims to provide broad-spectrum protection against a variety of potentially pandemic viruses, including in particular H5N1 avian influenza and coronaviruses such as SARS-CoV-2, SARS-CoV-1 and MERS-CoV. This is a paradigmatic departure from traditional vaccines that target only the strains currently circulating.
* Innovative Approach: BPL-inactivated whole virus vaccines are proposed to generate strong B and T cell immune responses and provide long-term protection against various virus families, as they eliminate the infectivity of the virus while preserving its structural integrity.
* Potential to Inhibit Transmission: An intranasal formulation (intranasal) called BPL-1357 is currently in Phase Ib and II/III trials. It is suggested that this formulation has the potential to prevent transmission of the virus, a feature not found in existing flu and COVID-19 vaccines.
Clinical Trials
Important steps are being taken for the future of this exciting platform:
* Clinical trials for universal flu vaccines are scheduled to begin in 2026.
* Food and Drug Administration (FDA) approval for both universal flu vaccines and intranasal BPL-1357 flu vaccine is targeted by 2029.
* In addition to influenza and coronavirus, the BPL platform could be adapted in the future for use against other viruses such as RSV, metapneumovirus and parainfluenza.
The development of such innovative vaccine platforms is critical to ensure we are better prepared for future pandemics. Our clinic will continue to follow developments in this field.
Reference: NIH ( National Instutues of Health)